These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 21562253)

  • 41. Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: A Case Report.
    Greenwood GT; Lynch Z
    Am J Case Rep; 2020 May; 21():e921431. PubMed ID: 32417849
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment of myasthenia gravis with intravenous immunoglobulin G (IVIG)].
    Lavrnić DB; Stojanović V; Marinković Z; Pavlović S; Vidaković A; Apostolski S
    Srp Arh Celok Lek; 1995; 123(5-6):146-8. PubMed ID: 17974459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies.
    Liblau R; Gajdos P; Bustarret FA; el Habib R; Bach JF; Morel E
    J Clin Immunol; 1991 May; 11(3):128-31. PubMed ID: 1716263
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of intravenous immunoglobulin and plasma exchange in critically ill patients.
    Clark SL; Rabinstein AA
    Neurol Res; 2015 Jul; 37(7):593-8. PubMed ID: 25751423
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Calcineurin inhibitors and IVIg in the treatment of myasthenia gravis].
    Nakane S
    Rinsho Shinkeigaku; 2013; 53(11):1309-11. PubMed ID: 24291970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions.
    Klemencic Kozul T; Yudina A; Donovan C; Pinto A; Osman C
    BMC Health Serv Res; 2022 Jul; 22(1):904. PubMed ID: 35831856
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose intravenous immunoglobulin G treatment of myasthenia gravis.
    Ferrero B; Durelli L
    Neurol Sci; 2002 Apr; 23 Suppl 1():S9-24. PubMed ID: 12032583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations.
    Karelis G; Balasa R; De Bleecker JL; Stuchevskaya T; Villa A; Van Damme P; Lagrange E; Heckmann JM; Nicolle M; Vilciu C; Bril V; Mondou E; Griffin R; Chen J; Henriquez W; Garcia B; Camprubi S; Ayguasanosa J
    Eur Neurol; 2019; 81(5-6):223-230. PubMed ID: 31655810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of thrombotic events after inpatient intravenous immunoglobulin or plasma exchange for neurologic disease: A case-crossover study.
    Jin PH; Shin SC; Dhamoon MS
    Muscle Nerve; 2020 Sep; 62(3):327-332. PubMed ID: 32270520
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis.
    Wegner B; Ahmed I
    Clin Neurol Neurosurg; 2002 Dec; 105(1):3-8. PubMed ID: 12445915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-dose intravenous immunoglobulin for the treatment of MuSK antibody-positive seronegative myasthenia gravis.
    Takahashi H; Kawaguchi N; Nemoto Y; Hattori T
    J Neurol Sci; 2006 Sep; 247(2):239-41. PubMed ID: 16876198
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing the comparative efficacy of plasmapheresis and Intravenous immunoglobulin in myasthenia gravis treatment: A systematic review and meta-analysis.
    Ghimire A; Kunwar B; Aryal B; Gaire A; Bist A; Shah B; Mainali A; Ghimire B; Gajurel BP
    J Clin Neurosci; 2024 Mar; 121():1-10. PubMed ID: 38306763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis.
    Howard JF
    Neurology; 1998 Dec; 51(6 Suppl 5):S30-6. PubMed ID: 9851728
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience.
    Pasnoor M; Wolfe GI; Nations S; Trivedi J; Barohn RJ; Herbelin L; McVey A; Dimachkie M; Kissel J; Walsh R; Amato A; Mozaffar T; Hungs M; Chui L; Goldstein J; Novella S; Burns T; Phillips L; Claussen G; Young A; Bertorini T; Oh S
    Muscle Nerve; 2010 Mar; 41(3):370-4. PubMed ID: 19882635
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuromuscular disease: acute treatment for myasthenia gravis.
    Gilhus NE
    Nat Rev Neurol; 2011 Mar; 7(3):132-4. PubMed ID: 21386868
    [No Abstract]   [Full Text] [Related]  

  • 57. Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis.
    Dalakas MC; Meisel A
    Expert Rev Neurother; 2022 Apr; 22(4):313-318. PubMed ID: 35350948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral corticosteroid therapy and present disease status in myasthenia gravis.
    Imai T; Suzuki S; Tsuda E; Nagane Y; Murai H; Masuda M; Konno S; Suzuki Y; Nakane S; Fujihara K; Suzuki N; Utsugisawa K
    Muscle Nerve; 2015 May; 51(5):692-6. PubMed ID: 25155615
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of Plasma Exchange Combined with Immunoglobulin Therapy on Consciousness, Immune Function, and Prognosis in Patients with Myasthenia Gravis Crisis: A Prospective Randomized Test.
    Peng X; Xie XB; Tan H; Zhang D; Jiang BT; Liu J; Li S; Chen YR; Xie TY
    Comput Math Methods Med; 2022; 2022():7796833. PubMed ID: 35813442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis.
    Guptill JT; Juel VC; Massey JM; Anderson AC; Chopra M; Yi JS; Esfandiari E; Buchanan T; Smith B; Atherfold P; Jones E; Howard JF
    Autoimmunity; 2016 Nov; 49(7):472-479. PubMed ID: 27684107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.